These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 35899617)

  • 1. Still a Long Way to the Precision Medicine of Antiplatelet Strategy After Percutaneous Coronary Intervention.
    Jeong YH; Obayashi Y; Song H; Kimura T
    Circ Cardiovasc Interv; 2022 Aug; 15(8):e012261. PubMed ID: 35899617
    [No Abstract]   [Full Text] [Related]  

  • 2. Individualizing Duration of Dual Antiplatelet Therapy After Acute Coronary Syndrome or Percutaneous Coronary Intervention.
    Bagai A; Bhatt DL; Eikelboom JW; Mancini GB; Cohen EA; Vijayaraghavan R; Cheema AN; Udell JA; Niznick J; Tanguay JF; Verma S; Mehta SR
    Circulation; 2016 May; 133(21):2094-8. PubMed ID: 27217435
    [No Abstract]   [Full Text] [Related]  

  • 3. Advocating cardiovascular precision medicine with P2Y12 receptor inhibitors.
    Winter MP; Grove EL; De Caterina R; Gorog DA; Ahrens I; Geisler T; Gurbel PA; Tantry U; Navarese EP; Siller-Matula JM
    Eur Heart J Cardiovasc Pharmacother; 2017 Oct; 3(4):221-234. PubMed ID: 28204303
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clopidogrel: the data, the experience, and the controversies.
    Sadanandan S; Singh IM
    Am J Cardiovasc Drugs; 2012 Dec; 12(6):361-74. PubMed ID: 23057989
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-Term P2Y
    Capodanno D; Angiolillo DJ
    Circulation; 2023 Jan; 147(2):118-121. PubMed ID: 36622905
    [No Abstract]   [Full Text] [Related]  

  • 6. Individualized dual antiplatelet therapy based on platelet function testing in patients undergoing percutaneous coronary intervention: a meta-analysis of randomized controlled trials.
    Zhou Y; Wang Y; Wu Y; Huang C; Yan H; Zhu W; Xu W; Zhang L; Zhu J
    BMC Cardiovasc Disord; 2017 Jun; 17(1):157. PubMed ID: 28619104
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of clopidogrel and potent P2Y 12 -inhibitors on mortality and stroke in patients with acute coronary syndrome or undergoing percutaneous coronary intervention: a systematic review and meta-analysis.
    Aradi D; Komócsi A; Vorobcsuk A; Serebruany VL
    Thromb Haemost; 2013 Jan; 109(1):93-101. PubMed ID: 23197191
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A practical approach to prescribing antiplatelet therapy in patients with acute coronary syndromes.
    Alkhalil M; Kuzemczak M; Bell A; Stern S; Welsford M; Cantor WJ; Goodman SG
    CMAJ; 2022 Feb; 194(6):E205-E215. PubMed ID: 35165132
    [No Abstract]   [Full Text] [Related]  

  • 9. Evolving role of platelet function testing in coronary artery interventions.
    Sharma RK; Voelker DJ; Sharma R; Reddy HK; Dod H; Marsh JD
    Vasc Health Risk Manag; 2012; 8():65-75. PubMed ID: 22371653
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ticagrelor monotherapy after coronary stenting in patients requiring proton pump inhibitor and prolonged antiplatelet therapy.
    Ashley KE; Hillegass WB
    Catheter Cardiovasc Interv; 2022 Jul; 100(1):83-84. PubMed ID: 35819146
    [No Abstract]   [Full Text] [Related]  

  • 11. Elderly patients with acute coronary syndromes managed without revascularization: insights into the safety of long-term dual antiplatelet therapy with reduced-dose prasugrel versus standard-dose clopidogrel.
    Roe MT; Goodman SG; Ohman EM; Stevens SR; Hochman JS; Gottlieb S; Martinez F; Dalby AJ; Boden WE; White HD; Prabhakaran D; Winters KJ; Aylward PE; Bassand JP; McGuire DK; Ardissino D; Fox KA; Armstrong PW
    Circulation; 2013 Aug; 128(8):823-33. PubMed ID: 23852610
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacodynamic Comparison of Ticagrelor Monotherapy Versus Ticagrelor and Aspirin in Patients After Percutaneous Coronary Intervention: The TEMPLATE (Ticagrelor Monotherapy and Platelet Reactivity) Randomized Controlled Trial.
    Johnson TW; Baos S; Collett L; Hutchinson JL; Nkau M; Molina M; Aungraheeta R; Reilly-Stitt C; Bowles R; Reeves BC; Rogers CA; Mundell SJ; Baumbach A; Mumford AD
    J Am Heart Assoc; 2020 Dec; 9(24):e016495. PubMed ID: 33305660
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical Utility of CYP2C19 Genotyping to Guide Antiplatelet Therapy in Patients With an Acute Coronary Syndrome or Undergoing Percutaneous Coronary Intervention.
    Klein MD; Williams AK; Lee CR; Stouffer GA
    Arterioscler Thromb Vasc Biol; 2019 Apr; 39(4):647-652. PubMed ID: 30760018
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Switching antiplatelet regimens: alternatives to clopidogrel in patients with acute coronary syndrome undergoing PCI: a review of the literature and practical considerations for the interventional cardiologist.
    Azmoon S; Angiolillo DJ
    Catheter Cardiovasc Interv; 2013 Feb; 81(2):232-42. PubMed ID: 22581463
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiplatelet therapy in acute coronary syndromes.
    Aragam KG; Bhatt DL
    J Cardiovasc Pharmacol Ther; 2011 Mar; 16(1):24-42. PubMed ID: 20924098
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antithrombotic Therapy in Patients With Atrial Fibrillation and Acute Coronary Syndrome Treated Medically or With Percutaneous Coronary Intervention or Undergoing Elective Percutaneous Coronary Intervention: Insights From the AUGUSTUS Trial.
    Windecker S; Lopes RD; Massaro T; Jones-Burton C; Granger CB; Aronson R; Heizer G; Goodman SG; Darius H; Jones WS; Aschermann M; Brieger D; Cura F; Engstrøm T; Fridrich V; Halvorsen S; Huber K; Kang HJ; Leiva-Pons JL; Lewis BS; Malaga G; Meneveau N; Merkely B; Milicic D; Morais J; Potpara TS; Raev D; Sabaté M; de Waha-Thiele S; Welsh RC; Xavier D; Mehran R; Alexander JH;
    Circulation; 2019 Dec; 140(23):1921-1932. PubMed ID: 31557056
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The use of dual antiplatelet therapy in high-risk patients with acute coronary syndromes.
    Guthrie RM
    J Fam Pract; 2015 Dec; 64(12 Suppl):. PubMed ID: 26845006
    [No Abstract]   [Full Text] [Related]  

  • 18. Benefit of Switching Dual Antiplatelet Therapy After Acute Coronary Syndrome According to On-Treatment Platelet Reactivity: The TOPIC-VASP Pre-Specified Analysis of the TOPIC Randomized Study.
    Deharo P; Quilici J; Camoin-Jau L; Johnson TW; Bassez C; Bonnet G; Fernandez M; Ibrahim M; Suchon P; Verdier V; Fourcade L; Morange PE; Bonnet JL; Alessi MC; Cuisset T
    JACC Cardiovasc Interv; 2017 Dec; 10(24):2560-2570. PubMed ID: 29268886
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ticagrelor: the silence of the platelets.
    Laine M; Paganelli F; Bonello L
    Expert Opin Pharmacother; 2013 Feb; 14(2):151-3. PubMed ID: 23294190
    [No Abstract]   [Full Text] [Related]  

  • 20. Platelet function testing and tailored antiplatelet therapy.
    Janssen PW; ten Berg JM
    J Cardiovasc Transl Res; 2013 Jun; 6(3):316-28. PubMed ID: 23543615
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.